Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Other Accumulated Expenses (2019 - 2025)

Summit Therapeutics (SMMT) has disclosed Other Accumulated Expenses for 7 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Other Accumulated Expenses rose 90.46% year-over-year to $2.0 million, compared with a TTM value of $2.0 million through Sep 2025, up 90.46%, and an annual FY2024 reading of $1.8 million, up 150.63% over the prior year.
  • Other Accumulated Expenses was $2.0 million for Q3 2025 at Summit Therapeutics, up from $1.5 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $2.0 million in Q3 2025 and bottomed at $209000.0 in Q3 2022.
  • Average Other Accumulated Expenses over 5 years is $828473.7, with a median of $717000.0 recorded in 2023.
  • The sharpest move saw Other Accumulated Expenses soared 190.96% in 2021, then plummeted 79.71% in 2022.
  • Year by year, Other Accumulated Expenses stood at $897000.0 in 2021, then dropped by 26.2% to $662000.0 in 2022, then increased by 8.31% to $717000.0 in 2023, then surged by 150.63% to $1.8 million in 2024, then increased by 8.85% to $2.0 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for SMMT at $2.0 million in Q3 2025, $1.5 million in Q2 2025, and $759000.0 in Q1 2025.